Approval · Notice of Compliance 34362 · 2024
IFEX: Notice of Compliance 34362
Issued November 12, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34362
- Date
- November 12, 2024
- Company
- Baxter CorporationMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information. Product Monograph reformatted to the Master Template. Update to package insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IFEX | Not yet assigned | — |
Medicinal ingredients
- IFOSFAMIDE 1 G per VIAL
- IFOSFAMIDE 3 G per VIAL